Drug-Coated Balloon versus Drug-Eluting Stent: The Debate of Leave Nothing Behind

Abstract

Endovascular techniques for peripheral artery disease have changed significantly in the past 10 years with advances in technology and data. Treatment of superficial femoral disease is complex secondary to the length, degree of calcification, high rate of chronic total occlusion, and areas of flexion within this vessel. Use of drug-coated devices has increased the interventionalist's toolbox with the objective to improve freedom from target lesion revascularization and primary patency. There remains debate as to which devices may reach these goals while also limiting overall morbidity and mortality. This article aims to highlight recent advances in the literature regarding the use of drug-coated devices.

Keywords

drug-eluting stent - drug-coated balloon - plain-old balloon angioplasty - bare metal stent - paclitaxel - percutaneous transluminal angioplasty - interventional radiology

Publication History

Article published online:
16 June 2023

• References

• 1 Ansel GM. Drug-coated balloons versus drug-eluting stents in the femoropopliteal artery: comparing apples to oranges?. J Cardiovasc Surg (Torino) 2019; 60 (04) 456-459
• 2 Jones WS, Patel MR, Dai D. et al. High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. Am Heart J 2013; 165 (05) 809-815 , 815.e1
• 3 Dua A, Lee CJ. Epidemiology of peripheral arterial disease and critical limb ischemia. Tech Vasc Interv Radiol 2016; 19 (02) 91-95
• 4 Lichtenberg MK, Carr JG, Golzar JA. Optical coherence tomography: guided therapy of in-stent restenosis for peripheral arterial disease. J Cardiovasc Surg (Torino) 2017; 58 (04) 518-527
• 5 Dalager S, Paaske WP, Kristensen IB, Laurberg JM, Falk E. Artery-related differences in atherosclerosis expression: implications for atherogenesis and dynamics in intima-media thickness. Stroke 2007; 38 (10) 2698-2705
• 6 Bennett MR. In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 2003; 89 (02) 218-224
• 7 Dake MD, Ansel GM, Jaff MR. et al; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 2016; 133 (15) 1472-1483 , discussion 1483
• 8 Keate BR, Cooper KJ. Anti-restenotic technologies in the SFA: balloons and stents. Tech Vasc Interv Radiol 2022; 25 (03) 100842
• 9 Lindquist J, Schramm K. Drug-eluting balloons and drug-eluting stents in the treatment of peripheral vascular disease. Semin Intervent Radiol 2018; 35 (05) 443-452
• 10 Scheinert D, Duda S, Zeller T. et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014; 7 (01) 10-19
• 11 Rosenfield K, Jaff MR, White CJ. et al; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 2015; 373 (02) 145-153
• 12 Thieme M, Von Bilderling P, Paetzel C, Karnabatidis D, Perez Delgado J, Lichtenberg M. Lutonix Global SFA Registry Investigators. The 24-month results of the Lutonix global SFA registry: worldwide experience with Lutonix drug-coated balloon. JACC Cardiovasc Interv 2017; 10 (16) 1682-1690
• 13 Steiner S, Willfort-Ehringer A, Sievert H. et al; RANGER SFA Investigators. 12-month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv 2018; 11 (10) 934-941
• 14 Lichtenberg M, von Bilderling P, Ranft J. et al. Treatment of femoropopliteal atherosclerotic lesions using the ranger paclitaxel-coated balloon catheter: 12-month results from an all-comers registry. J Cardiovasc Surg (Torino) 2018; 59 (01) 45-50
• 15 Endovascular Today. Accessed April 8, 2023 at: https://evtoday.com/2018/05/09/ranger-sfa-12-month-data-published-for-boston-scientifics-ranger-dcb
• 16 Tepe G, Laird J, Schneider P. et al; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation 2015; 131 (05) 495-502
• 17 Schneider PA, Laird JR, Tepe G. et al; IN.PACT SFA Trial Investigators. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv 2018; 11 (01) e005891
• 18 Laird JA, Schneider PA, Jaff MR. et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions: five-year outcomes from the IN.PACT SFA randomized trial. Circ Cardiovasc Interv 2019; 12 (06) e007702
• 19 Schroeder H, Werner M, Meyer DR. et al; ILLUMENATE EU RCT Investigators. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation 2017; 135 (23) 2227-2236
• 20 Krishnan P, Faries P, Niazi K. et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation 2017; 136 (12) 1102-1113
• 21 Brodmann M, Werner M, Meyer DR. et al; ILLUMENATE EU RCT Investigators. Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE Euro- pean randomized clinical trial 2-year results. JACC Cardiovasc Interv 2018; 11 (23) 2357-2364
• 22 Gray WA, Jaff MR, Parikh SA. et al. Mortality assessment of paclitaxel- coated balloons: patient-level meta-analysis of the ILLUMENATE clinical program at 3 years. Circulation 2019; 140 (14) 1145-1155
• 23 Teichgräber U, Lehmann T, Aschenbach R. et al. Two-year review on mortality and morbidity after femoropopliteal drug-coated balloon angioplasty in the Randomized EffPac Trial. Radiology 2020; 296 (03) 638-640
• 24 Tang TY, Yap CJ, Chan SL. et al. Safety and efficacy of Luminor™ balloon and Angiolite™ stent on TASC C/D tibial occlusive lesions in CLI patients: 12-month results. The MERLION trial. Int Angiol 2021; 40 (04) 335-344
• 25 Teichgräber U, Lehmann T, Ingwersen M. et al. Long-term effectiveness and safety of femoropopliteal drug-coated balloon angioplasty: 5-year results of the Randomized Controlled EffPac Trial. Cardiovasc Intervent Radiol 2022; 45 (12) 1774-1783
• 26 Krishnan P, Purushothaman KR, Purushothaman M. et al. Histological features of restenosis associated with paclitaxel drug-coated balloon: implications for therapy. Cardiovasc Pathol 2019; 43: 107139
• 27 Gray WA, Keirse K, Soga Y. et al; IMPERIAL Investigators. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 2018; 392 (10157): 1541-1551
• 28 Müller-Hülsbeck S, Keirse K, Zeller T, Schroë H, Diaz-Cartelle J. Long-term results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up. Cardiovasc Intervent Radiol 2017; 40 (12) 1832-1838
• 29 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 7 (24) e011245
• 30 Kim TI, Kiwan G, Mohamedali A. et al. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. J Vasc Surg 2021; 73 (03) 911-917
• 31 Shishehbor MH, Secemsky EA, Varcoe RL. Is there a real association between paclitaxel devices and mortality? Time to pause and reevaluate what we know about this statistical finding. J Am Heart Assoc 2019; 8 (10) e012524
• 32 Wang J, Chen X, Zhao J, Zhang WW. Systematic review and meta-analysis of the outcomes of drug-eluting stent versus drug-coated balloon angioplasty for lower extremity peripheral artery diseases. Ann Vasc Surg 2022; 85: 1-8.e5
• 33 Dake MD, Ansel GM, Bosiers M. et al. Paclitaxel-coated Zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices. Cardiovasc Intervent Radiol 2020; 43 (01) 8-19
• 34 Secemsky EA, Kundi H, Weinberg I. et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol 2019; 4 (04) 332-340
• 35 Secemsky EA, Kundi H, Weinberg I. et al. Drug-eluting stent implantation and long-term survival following peripheral artery revascularization. J Am Coll Cardiol 2019; 73 (20) 2636-2638
• 36 Liistro F, Angioli P, Porto I. et al. Drug-eluting balloon versus drug-eluting stent for complex femoropopliteal arterial lesions: the DRASTICO study. J Am Coll Cardiol 2019; 74 (02) 205-215
• 37 Bausback Y, Wittig T, Schmidt A. et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease. J Am Coll Cardiol 2019; 73 (06) 667-679
• 38 Marzlin N, Jan MF, Kostopoulos L, Moreno ACP, Bajwa T, Allaqaband SQ. Peripheral artery disease intervention: drug-coated balloon vs drug-eluting stent, a long-term comparison. J Interv Cardiol 2022; 2022: 5175607
• 39 Koifman E, Lipinski MJ, Buchanan K. et al. Comparison of treatment strategies for femoro-popliteal disease: a network meta-analysis. Catheter Cardiovasc Interv 2018; 91 (07) 1320-1328
• 40 Sridharan ND, Boitet A, Smith K. et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. J Vasc Surg 2018; 67 (01) 343-352
• 41 Deloose K, Callaert J. Less is more: the “As Less As Reasonably Achievable Stenting” (ALARAS) strategy in the femoropopliteal area. J Cardiovasc Surg (Torino) 2018; 59 (04) 495-503
• 42 Schroë H, Holden AH, Gouëffic Y. et al. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease - the ILLUMENATE Global Study: 12-month results from a prospective, multicenter, single-arm study. Catheter Cardiovasc Interv 2018; 91 (03) 497-504
• 43 Tepe G, Zeller T, Schnorr B. et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther 2013; 20 (06) 792-800
• 44 Shishehbor MH, Scheinert D, Jain A. et al. Comparison of drug-coated balloons vs bare-metal stents in patients with femoropopliteal arterial disease. J Am Coll Cardiol 2023; 81 (03) 237-249
• 45 Lee YJ, Kook H, Ko YG. et al. Drug eluting stent vs. drug coated balloon for native femoropopliteal artery disease: a two centre experience. Eur J Vasc Endovasc Surg 2021; 61 (02) 287-295
• 46 Castro-Dominguez Y, Smolderen KG, Pichert M. et al. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. J Vasc Surg 2022; 76 (06) 1675-1680
• 47 Phair J, Carnevale M, Lipsitz EC. et al. Amputation-free survival in patients with critical limb ischemia treated with paclitaxel-eluting stents and paclitaxel-coated balloons. Ann Vasc Surg 2020; 62: 8-14